The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.00 (0.00%)
Spread: 1.25 (6.793%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.65
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HIV Testing Certification

23 Mar 2012 07:00

RNS Number : 9058Z
BATM Advanced Communications Ld
23 March 2012
 



23 March 2012

 

BATM Advanced Communications Limited

CE certification for HIV screening kit

 

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is delighted to announce that its fully owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its Detect HIV 4th generation (AIDS 4th generation ) Total Screening Kit.

The kit is able to detect simultaneously HIV 1&2 antibodies and HIV p24 antigens, with the 4th generation screening able to detect the latest strains of the virus. Testing in external, independent labs has shown performance results of 100% accuracy for diagnostic sensitivity and 99.7% for diagnostic specifity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnosis and that laboratories are spared the significant and needless expense of repeat testing.

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

Dr Zvi Marom, Chief Executive, of BATM commented:

"The sensitivity and specifity performance levels of our Total Screening Kit are clearly outstanding and we are delighted to have received CE certification. We have received great interest in this product and certification now allows us to increase sales in several territories.

"This important step in our medical division augurs well for its future with the prospect of improved margins and sales. The Company is encouraged that its success with this kit will extend to other kits that are under certifications."

 

- Ends -

For further information:

Enquiries

BATM Advanced Communications +972 9866 2527Ofer Bar-Ner, CFO

Newgate Threadneedle 020 7653 9850Josh Royston / Graham Herring

finnCap 020 7220 0500Marc Young / Brian Patient

Shore Capital 020 7408 4090 Pascal Keane

Notes to Editors

According to a report in January 2012 from TriMarkPublications.com, there are an estimated 33.3 million people living with HIV worldwide and approximately 2.6 million people are newly infected each year. Although the Asian and African regions account for more than 90% of the HIV-infected population, the U.S. and European regions make up greater than 60% of the HIV testing market.

The same report also states that the global HIV-AIDS testing market is forecasted to catapult to $4.4 billion by 2016.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEDFMEFESESD
Date   Source Headline
2nd May 20247:00 amRNSBATM selected for TB diagnostics programme
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.